Myleran (Busulfan)

Busulfan alkylates DNA at specific guanine sites, creating cross‑links that block DNA replication and transcription. This damage leads to cell cycle arrest and apoptosis, especially in rapidly dividing hematopoietic and leukemic cells, providing its antineoplastic effect.

The dosage of Myleran is individualized and determined by the prescribing physician based on the patient’s condition, weight, treatment protocol, and laboratory monitoring. Exact dosing regimens should be obtained from the treating clinician.

Busulfan is classified as pregnancy category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and breastfeeding is contraindicated because the drug can be excreted in milk and may harm the infant.

To request Myleran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Busulfan is an alkylating agent that provides myeloablation through DNA cross‑linking, whereas alternatives such as total body irradiation or other chemotherapeutics (e.g., cyclophosphamide) use different mechanisms. Busulfan offers oral administration and predictable pharmacokinetics but requires careful monitoring for organ toxicity.

Myleran oral solution should be stored at ambient temperature, preferably below 25 °C. Keep the container tightly closed, protect it from moisture and light, and store it in the original packaging until use.

Myleran is supplied as an oral solution and is taken by mouth according to the prescribing physician’s instructions. The dose is usually divided over several days and may be given with or without food, depending on the treatment protocol.

Serious risks include pulmonary fibrosis, hepatic veno‑occlusive disease, seizures, and severe bone marrow failure. Patients should be monitored closely for respiratory symptoms, liver dysfunction, neurological changes, and profound cytopenias throughout therapy.

Myleran is contraindicated in patients with known hypersensitivity to Busulfan, in pregnant or nursing women, and in individuals with severe hepatic or pulmonary impairment where the risk of toxicity outweighs potential benefit.